Global Tolbutamide (CAS 64-77-7) Market Size By Type (Oral, Injection), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Tolbutamide (CAS 64-77-7) Market was valued at USD 118.6 million in 2023 and is projected to reach USD 165.3 million by 2031, growing at a CAGR of 4.2% during the forecast period from 2023 to 2031. Tolbutamide, a first-generation sulfonylurea, remains a key pharmaceutical compound used primarily for the management of type 2 diabetes mellitus. Despite the emergence of newer antidiabetic drugs, Tolbutamide continues to witness stable demand in developing economies due to its cost-effectiveness and well-documented clinical efficacy. The global market is driven by consistent demand in generic pharmaceutical formulations and increasing diabetes prevalence, especially in low- and middle-income countries.

Drivers

1. Rising Prevalence of Diabetes Globally:

As the global burden of type 2 diabetes continues to grow, especially in Asia-Pacific, Africa, and Latin America, the need for effective and affordable antidiabetic medications like Tolbutamide remains strong.

2. Affordability and Generic Drug Accessibility:

Tolbutamide's affordability and extensive availability in generic form make it a preferred choice in price-sensitive markets, where newer treatments are not as accessible.

3. Expansion of Pharmaceutical Manufacturing in Emerging Economies:

Increased pharmaceutical manufacturing capabilities in regions like South Asia and Africa are supporting Tolbutamide production and market accessibility.

Restraints

1. Declining Preference in Developed Markets:

The growing inclination toward newer-generation oral antidiabetics, such as DPP-4 inhibitors and SGLT2 inhibitors, has reduced Tolbutamide's share in developed countries.

2. Risk of Hypoglycemia:

Tolbutamide carries a higher risk of inducing hypoglycemia compared to newer antidiabetic agents, which can limit its use among elderly patients and those with comorbidities.

Opportunity

1. Government-Supported Generic Drug Programs:

Government initiatives promoting affordable healthcare and increasing the availability of essential generic drugs are expected to bolster Tolbutamide demand in public health sectors.

2. Strategic Collaborations and Licensing:

Partnerships between global pharmaceutical companies and regional manufacturers may facilitate large-scale distribution and localized production, especially across Asia-Pacific and Sub-Saharan Africa.

Market by System Type Insights

By system type, API-grade Tolbutamide accounted for the largest share in 2023, driven by its direct supply to local pharmaceutical manufacturers for formulation into tablets. Meanwhile, Formulated Tablet Segment is expected to grow steadily due to increasing over-the-counter sales and inclusion in essential medicine lists in several developing nations.

Market by End-use Insights

Hospitals and public healthcare institutions represent the dominant end-use segment, particularly in regions with government-funded medication programs. The Retail Pharmacy sector is expected to see the fastest growth rate owing to greater accessibility for non-hospitalized diabetes patients in rural and semi-urban regions.

Market by Regional Insights

Asia-Pacific led the global Tolbutamide market in 2023, accounting for over 45% of the market share, driven by high diabetes prevalence, government-driven generic drug programs, and low-cost production capabilities in countries like India and China. Latin America and Africa are poised for substantial growth due to expanding healthcare infrastructure and the growing availability of generic pharmaceuticals. North America and Europe, while showing lower growth, still contribute a consistent share due to legacy prescriptions and niche use cases.

Competitive Scenario

Key players in the Global Tolbutamide Market include:

Teva Pharmaceutical Industries Ltd.

Zydus Lifesciences Ltd.

Cipla Ltd.

Mylan N.V.

Sun Pharmaceutical Industries Ltd.

Sanofi S.A.

Pfizer Inc.

Glenmark Pharmaceuticals

Apotex Inc.

Intas Pharmaceuticals Ltd.

These companies are focusing on expanding production capabilities, improving distribution networks, and maintaining compliance with international regulatory standards.

Scope of Work – Global Tolbutamide (CAS 64-77-7) Market

Key Market Developments

2023: Cipla Ltd. expanded its Tolbutamide production in India as part of a broader initiative to supply essential generics to African nations.

2024: Glenmark Pharmaceuticals launched a fixed-dose combination therapy including Tolbutamide to target cost-sensitive diabetic populations in Southeast Asia.

2025: Sanofi signed a supply agreement with multiple African governments for bulk distribution of essential diabetes medications including Tolbutamide.

FAQs

1) What is the current market size of the Global Tolbutamide (CAS 64-77-7) Market?

The market was valued at USD 118.6 million in 2023.

2) What is the major growth driver of the Global Tolbutamide (CAS 64-77-7) Market?

The primary driver is the rising prevalence of diabetes, especially in developing regions, combined with the affordability of Tolbutamide.

3) Which is the largest region during the forecast period in the Global Tolbutamide (CAS 64-77-7) Market?

Asia-Pacific is the largest and fastest-growing region due to high disease burden and strong generic drug infrastructure.

4) Which segment accounted for the largest market share in Global Tolbutamide (CAS 64-77-7) Market?

The API-grade Tolbutamide segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Tolbutamide (CAS 64-77-7) Market?

Key players include Teva, Cipla, Sun Pharma, Mylan, Sanofi, and Pfizer.